About Myriad Genetics, Inc
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. Address: 320 Wakara Way, Salt Lake City, UT, United States, 84108
Myriad Genetics, Inc News and around…
Latest news about Myriad Genetics, Inc (MYGN) common stock and company :
New legal leader brings healthcare expertise from Quest Diagnostics and experience at major global law firmsSALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Pamela Wong as its new Chief Legal Officer. In her role, she is responsible for leading the company’s legal function, including support and counsel for all legal affairs, intellectual property, patent protection, merg
Figure 1: Among those who say they would not seek treatment Things that would lead a person to seek treatment for anxiety SALT LAKE CITY, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they won’t seek treatment for mental health conditions and others say they won’t get help until these symptoms take a toll in their lives. Nearly half (46%) of all respondents rated their anxiety symptoms as moderate to severe ov
Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.
NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of CarLotz, Inc. (NASDAQ: LOTZ), Myriad Genetics, Inc. (NASDAQ: MYGN), and AMC Entertainment Holdings, Inc. (NYSE: AMC) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. CarLotz, Inc. (NASDAQ: LOTZ) Bragar Eagel & Squire is investigating certain officers and d
Nicole Lambert, Corporate Officer at Myriad Genetics (NASDAQ:MYGN), made a large insider sell on September 27, according to a new SEC ...
Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.
Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. The HRD tests will leverage Illumina's TruSight™ Oncology 500 (TSO 500) content, enabling the most compreh
Agilent Technologies (A) boosts presence in the companion diagnostics market by expanding the use of PD-L1 IHC 22C3 pharmDx assay for esophageal cancer treatment in Europe.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Myriad Genetics, Inc...
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company ...
MYGN earnings call for the period ending June 30, 2021.
Myriad Genetics, Inc. (NASDAQ: MYGN) shares are trading higher by 12.4% at $34.68 Tuesday afternoon after the company reported ...
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed ...
Myriad (MYGN) delivered earnings and revenue surprises of 271.43% and 13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth ...
Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
GeneSight® Mental Health Monitor finds large gap between what Americans think and what they actually know about recognizing depression
Myriad Genetics, Inc (MYGN) is a NASDAQ Common Stock listed in Common Stock, Diagnostics & Research, Healthcare
